New Website Addresses Epidermal Growth Factor Receptors in Cancer Therapy

Publication
Article
OncologyONCOLOGY Vol 14 No 6
Volume 14
Issue 6

AstraZeneca has announced the launch of a new website that will help keep researchers and physicians up to date on

AstraZeneca has announced the launch of a new website that will help keep researchers and physicians up to date on the latest information and developments concerning epidermal growth factor receptors (EGFRs).

The website—EGFR-INFO.com—is designed for health and medical professionals only and is password protected. This source of comprehensive information on the role of EGFRs in cancer includes the following sections:

A complete guide to EGFRs and cancer—including the potential role of these receptors in the treatment of cancer—illustrated through graphic animations, which can be requested on CD-ROM

A slide library that can be downloaded from the site and will be expanded and updated regularly as more information becomes available

Reports from international medical congresses and netcasts from important satellite symposia

A weekly update on the latest abstracts and information on EGFRs, with hyperlinks to full articles

A section containing the most frequently asked questions, along with the opportunity to submit questions to be answered by leading experts

The opportunity to search the Medline and CancerLit databases

Hyperlinks to a range of EGFR and cancer sites on the Web

Biological Background

Clinical data suggest that excessive levels of EGFR are linked to poor prognosis, including tumor invasion and development of metastases in some types of cancer. Epidermal growth factor receptors are expressed or overexpressed in a variety of common solid tumors, including non–small-cell lung cancer, colorectal cancer, ovarian cancer, prostate cancer, and gastric cancer.

Recent Videos
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
Related Content